Ambrx Biopharma Inc.

An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors

Takeouts, neuroscience innovation and investor sentiment to kick off 2024

Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment

A fall 2022 reset positioned an ADC for prostate cancer as the biotech’s top priority under new leadership

Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIH

Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more

Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more 

Plus Stegmeier joins Curie Bio and updates from Actinium, Lexeo and more

Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more

Plus Vraniak joins Inversago as CFO and updates from Thabor, Glympse, Civetta and more